Seagen Inc. announced that clinically meaningful progression-free survival, a secondary endpoint, was observed in a Phase 2 study evaluating the antibody-drug conjugate ADCETRIS® in combination with the PD-1 inhibitor nivolumab and standard chemotherapy agents doxorubicin and dacarbazine as first-line treatment for early and advanced stage classical Hodgkin lymphoma.
